Research Symposium

As a member of the Roseman University community or as a guest, you are invited to attend the 5th Annual Research Symposium on March 6, 2019. This event will be held at both the Henderson and South Jordan Campuses.

Utah

March 6th, 2019 | 2pm to 5:30pm MST
Roseman University of Health Sciences
South Jordan Campus
10920 S. River Front Pkwy | South Jordan, UT | 84095

Keynote Speaker

Rena D’Souza DDS, MS, PhD

President, International Association for Dental Research (IADR)
Professor of Dentistry & Assistant Vice President of Academic Affairs & Education, Health Sciences, University of Utah

Topic: How Science and Technology Advances Impact Oral Health : IADR’s Vision for the Next Century

Rena D’Souza is Professor of Dental Sciences, Neurobiology & Anatomy, Pathology and Surgery at the University of Utah. She currently serves as Assistant Vice President for Academic Affairs and Education for the Health Sciences. As a clinician-scientist, D’Souza has been strongly committed to discovery and mentoring throughout her academic career. She is a past president of the American Association for Dental Research (or, AADR) and is the current President of IADR, the largest global dental research organization with about 12,000 members in over 100 countries worldwide. at the conclusion of this meeting. Dr. D’Souza has authored over 150 publications and book chapters and has maintained an active research program for over 35 years through grant awards from the National Institutes of Health and other agencies. She has also led two major NIH-funded institutional grants that supported the research training of dentists and dentists-scientists at the predoctoral and postdoctoral levels. She received the 2002 Distinguished Scientist Award from the International Association for Dental Research (IADR) and the Presidential Award for Research Excellence from the Texas A&M Health Science Center in 2010. She was also inducted into the German National Academy of Sciences in 2012. Dr. D’souza was recognized as the Columbia University College of Dental Medicine’s Birnberg Research Medal in 2016. Dr. D’Souza is the proud recipient of over 15 dean’s teaching excellence awards and is the 2017 Irwin D. Mandel Distinguished Mentoring Awardee.

Download Utah 2018 Program
Download Utah 2017 Program
Download Utah 2017 Abstract Book

Nevada

March 6th, 2019 | 2pm to 6:30pm PST
Roseman University of Health Sciences
Henderson Campus
11 Sunset Way | Henderson, NV | 89014

Keynote Speaker

David R. Powell, M.D.

Senior Vice President, Metabolism Research
Pharmaceutical Biology Department
Lexicon Pharmaceuticals, Inc.
The Woodlands, TX

Topic: Sotagliflozin as an Adjunct to Insulin for Patients with Type 1 Diabetes

Dr. David R. Powell is a Senior Vice President over Metabolism Research at Lexicon Pharmaceuticals. He received his Doctor of Medicine from the University of Medicine and Dentistry of New Jersey following a bachelor’s degree in biology from Rutgers University. Following residencies in Pediatrics, Pediatric Nephrology, and Pediatric Endocrinology at the Medical University of South Carolina, University of California-San Francisco, and Stanford University, Dr. Powell joined Baylor College of Medicine as an Assistant Professor in the Department of Pediatrics, Division of Nephrology. By the time he left Baylor in 2004, he was a Professor of Pediatric Nephrology. He joined Lexicon Pharmaceuticals in The Woodlands, Texas as the Director of Metabolism Research.

While at Baylor, Dr. Powell studied ways to treat linear growth failure in children with chronic kidney disease (CKD). His studies demonstrated that growth hormone (GH) increased linear growth in an animal CKD model, a finding that predated clinical data showing that GH improves final adult height of people with CKD. His research group also found that FKHR (now known as FoxO1) was the protein that conferred the negative effect of insulin on hepatic gene transcription. At Lexicon Pharmaceuticals, Dr. Powell has used mouse gene knockouts (KOs) to identify drug targets. His group searched for metabolism drug targets within the nearly 5000 knockouts of druggable genes shared by mice and humans. Through this effort, Dr. Powell identified SGLT1 and SGLT2 as superior targets leading to the development of sotagliflozin (LX4211), an orally delivered dual SGLT1/SGLT2 inhibitor that improved glycemic control in clinical trials. His group has also developed LX2761, an SGLT1 inhibitor restricted to the intestine, which is undergoing clinical trials. They also studied Xermelo, an oral tryptophan hydroxylase (TPH) inhibitor that lowers serotonin production and treats carcinoid syndrome diarrhea, and performed preclinical studies for LX1031, a TPH inhibitor that provided significant relief to subjects with diarrhea-predominant irritable bowel syndrome. He has also developed antibodies that lower lipid levels and developed inhibitors of Notum, a Wnt deacetylase, which are bone anabolic agents. His group has also found a number of other key genes that are involved in obesity and diabetes, including polymorphisms that are linked to diabetes risk, as well as genes that influence bone mass in humans.

Download Nevada 2018 Program
Download Nevada 2017 Program
Download Nevada 2017 Abstract Book